BRPI0508633A - identificação de antìgenos próprios e não próprios envolvidos em doenças auto-imunes - Google Patents
identificação de antìgenos próprios e não próprios envolvidos em doenças auto-imunesInfo
- Publication number
- BRPI0508633A BRPI0508633A BRPI0508633-7A BRPI0508633A BRPI0508633A BR PI0508633 A BRPI0508633 A BR PI0508633A BR PI0508633 A BRPI0508633 A BR PI0508633A BR PI0508633 A BRPI0508633 A BR PI0508633A
- Authority
- BR
- Brazil
- Prior art keywords
- self
- identification
- involved
- autoimmune diseases
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
IDENTIFICAçãO DE ANTìGENOS PRóPRIOS E NãO PRóPRIOS ENVOLVIDOS EM DOENçAS AUTO-IMUNES A presente invenção proporciona peptídeos isolados relacionados à doença auto-imune pênfigo vulgar. Os peptídeos relacionados ao pênfigo vulgar são epítopos próprios derivados de patógenos humanos que estão envolvidos na etiologia e remissão da doença. Preparações farmacêuticas para tolerização e/ou imunização dos indivíduos são proporcionadas, bem como métodos relacionados aos mesmos. Métodos são proporcionados para identificação de outros epítopos próprios e não próprios envolvidos na doença auto-imune humana e preparações farmacêuticas similares e métodos de uso para estes epítopos são também fornecidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/799,005 US7084247B2 (en) | 2004-03-11 | 2004-03-11 | Identification of self and non-self antigens implicated in autoimmune diseases |
PCT/US2005/008326 WO2005087261A2 (en) | 2004-03-11 | 2005-03-10 | Identification of self and non-self antigens implicated in autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0508633A true BRPI0508633A (pt) | 2007-08-07 |
Family
ID=34920407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508633-7A BRPI0508633A (pt) | 2004-03-11 | 2005-03-10 | identificação de antìgenos próprios e não próprios envolvidos em doenças auto-imunes |
Country Status (17)
Country | Link |
---|---|
US (2) | US7084247B2 (pt) |
EP (1) | EP1732595A2 (pt) |
JP (1) | JP2007528422A (pt) |
KR (1) | KR20070026450A (pt) |
CN (1) | CN1942202A (pt) |
AP (1) | AP2006003735A0 (pt) |
AU (1) | AU2005221712A1 (pt) |
BR (1) | BRPI0508633A (pt) |
CA (1) | CA2559065A1 (pt) |
EA (1) | EA200601671A1 (pt) |
IL (1) | IL177961A0 (pt) |
MA (1) | MA28525B1 (pt) |
MX (1) | MXPA06010364A (pt) |
NO (1) | NO20064610L (pt) |
TN (1) | TNSN06273A1 (pt) |
WO (1) | WO2005087261A2 (pt) |
ZA (1) | ZA200607552B (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7084247B2 (en) * | 2004-03-11 | 2006-08-01 | Peptimmune, Inc. | Identification of self and non-self antigens implicated in autoimmune diseases |
US20070093449A1 (en) * | 2005-10-14 | 2007-04-26 | De Porre Peter M R | Novel IV formulation of tipifarnib |
DE602007005349D1 (de) * | 2006-01-17 | 2010-04-29 | Organon Nv | SELEKTIVE ENZYMATISCHE HYDROLYSE VON C-TERMINALEN tert-BUTYL-PEPTIDESTERN |
US8378072B2 (en) * | 2006-04-13 | 2013-02-19 | Declion Pharmaceuticals, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
JP2009069050A (ja) * | 2007-09-14 | 2009-04-02 | Nec Corp | 化合物のカラム担体への固定化方法 |
WO2009051797A1 (en) * | 2007-10-16 | 2009-04-23 | Peptimmune, Inc. | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
NZ589302A (en) * | 2008-04-17 | 2012-11-30 | Declion Pharmaceuticals Inc | Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders |
ES2381849T3 (es) | 2008-11-17 | 2012-06-01 | Borealis Ag | Procedimiento multietapa para producir polietileno con formación de gel reducida |
CA2761907A1 (en) * | 2009-05-14 | 2010-11-18 | Oatmeal Biotechnologies Group, L.L.C. | Platform technologies for spontaneously occurring diseases |
GB201112806D0 (en) * | 2011-07-26 | 2011-09-07 | Bauer Johann | Use of epitopes inducing specific tolerance for the prevention of tissue rejection |
EP2570455A1 (en) | 2011-09-16 | 2013-03-20 | Borealis AG | Polyethylene composition with broad molecular weight distribution and improved homogeneity |
EP2599828A1 (en) | 2011-12-01 | 2013-06-05 | Borealis AG | Multimodal polyethylene composition for the production of pipes with improved slow crack growth resistance |
US11458199B2 (en) * | 2012-08-21 | 2022-10-04 | Opko Pharmaceuticals, Llc | Liposome formulations |
EP2730612B1 (en) | 2012-11-09 | 2016-09-14 | Abu Dhabi Polymers Company Limited (Borouge) | Polymer composition comprising a blend of a multimodal polyethylene and a further ethylene polymer suitable for the production of a drip irrigation pipe |
EP2730611B1 (en) | 2012-11-09 | 2017-01-04 | Abu Dhabi Polymers Company Limited (Borouge) | Drip irrigation pipe comprising a polymer composition comprising a multimodal polyethylene base resin |
EP2740761B1 (en) | 2012-12-05 | 2016-10-19 | Borealis AG | Polyethylene composition with improved balance of slow crack growth resistance, impact performance and pipe pressure resistance for pipe applications |
EP2860200B1 (en) | 2013-10-10 | 2017-08-02 | Borealis AG | Polyethylene composition for pipe and pipe coating applications |
EP2860204B1 (en) | 2013-10-10 | 2018-08-01 | Borealis AG | Polyethylene composition for pipe applications |
PL2860202T3 (pl) | 2013-10-10 | 2018-11-30 | Borealis Ag | Polietylen odporny na wysoką temperaturę i sposób jego wytwarzania |
EP2860201A1 (en) | 2013-10-10 | 2015-04-15 | Borealis AG | High temperature resistant polyethylene and process for the production thereof |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
US20160310584A1 (en) * | 2013-12-06 | 2016-10-27 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
KR20160101073A (ko) | 2013-12-20 | 2016-08-24 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
US10301370B2 (en) * | 2014-05-02 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor T cells |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
MY190974A (en) | 2015-05-20 | 2022-05-25 | Massachusetts Gen Hospital | Shared neoantigens |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
KR102593922B1 (ko) | 2018-10-31 | 2023-10-25 | 보레알리스 아게 | 개선된 균질성을 갖는 고압력 저항성 파이프용 폴리에틸렌 조성물 |
EP3647645A1 (en) | 2018-10-31 | 2020-05-06 | Borealis AG | Polyethylene composition for high pressure resistant pipes |
AU2019388183B2 (en) | 2018-11-28 | 2022-03-24 | Abu Dhabi Polymers Co. Ltd (Borouge) L.L.C. | Polyethylene composition for film applications |
US20220282074A1 (en) | 2019-07-22 | 2022-09-08 | Abu Dhabi Polymers Co. Ltd (Borouge) L.L.C., | Single site catalysed multimodal polyethylene composition |
EP4019583B1 (en) | 2020-12-28 | 2024-04-10 | ABU DHABI POLYMERS CO. LTD (BOROUGE) - Sole Proprietorship L.L.C. | Polyethylene composition for film applications with improved toughness and stiffness |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4973577A (en) * | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
US5260422A (en) | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
US5194425A (en) * | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
US5130297A (en) * | 1988-06-23 | 1992-07-14 | Anergen, Inc. | Conjugates useful in ameliorating autoimmunity MHC-II-peptide |
WO1990008161A1 (en) | 1989-01-12 | 1990-07-26 | The Blood Center Of Southeastern Wisconsin | Peptide-mediated modulation of t-cell recognition as a means of affecting immune responses |
CA2106567A1 (en) | 1991-03-22 | 1992-09-23 | William V. Williams | Method of modulating mammalian t-cell response |
AU3178393A (en) | 1991-11-27 | 1993-06-28 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use |
US5719064A (en) | 1992-08-31 | 1998-02-17 | Oklahoma Medical Research Foundation | Peptide diagnostics and therapeutics for spondyloarthropathies |
AU4851893A (en) | 1992-09-11 | 1994-04-12 | Washington University | Peptides tolerizing t-cells and compositions thereof |
EP0726708A1 (en) | 1993-11-05 | 1996-08-21 | Pathogenesis Corporation | Virus associated multiple sclerosis: treatments, prevention and diagnosis thereof |
US6329499B1 (en) * | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
US5874531A (en) * | 1995-03-07 | 1999-02-23 | President And Fellows Of Harvard College | Identification of self and non-self antigens implicated autoimmune disease |
AU767185B2 (en) * | 1998-03-23 | 2003-11-06 | President And Fellows Of Harvard College | Synthesis of compounds and libraries of compounds |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US7084247B2 (en) * | 2004-03-11 | 2006-08-01 | Peptimmune, Inc. | Identification of self and non-self antigens implicated in autoimmune diseases |
-
2004
- 2004-03-11 US US10/799,005 patent/US7084247B2/en not_active Expired - Fee Related
-
2005
- 2005-03-10 AU AU2005221712A patent/AU2005221712A1/en not_active Abandoned
- 2005-03-10 MX MXPA06010364A patent/MXPA06010364A/es not_active Application Discontinuation
- 2005-03-10 EA EA200601671A patent/EA200601671A1/ru unknown
- 2005-03-10 AP AP2006003735A patent/AP2006003735A0/xx unknown
- 2005-03-10 CA CA002559065A patent/CA2559065A1/en not_active Abandoned
- 2005-03-10 WO PCT/US2005/008326 patent/WO2005087261A2/en active Application Filing
- 2005-03-10 KR KR1020067021038A patent/KR20070026450A/ko not_active Application Discontinuation
- 2005-03-10 EP EP05751786A patent/EP1732595A2/en not_active Withdrawn
- 2005-03-10 JP JP2007503086A patent/JP2007528422A/ja active Pending
- 2005-03-10 BR BRPI0508633-7A patent/BRPI0508633A/pt not_active IP Right Cessation
- 2005-03-10 CN CNA2005800109681A patent/CN1942202A/zh active Pending
-
2006
- 2006-03-23 US US11/388,121 patent/US20060159672A1/en not_active Abandoned
- 2006-09-07 IL IL177961A patent/IL177961A0/en unknown
- 2006-09-08 ZA ZA200607552A patent/ZA200607552B/en unknown
- 2006-09-11 TN TNP2006000273A patent/TNSN06273A1/en unknown
- 2006-10-11 NO NO20064610A patent/NO20064610L/no not_active Application Discontinuation
- 2006-10-11 MA MA29378A patent/MA28525B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR20070026450A (ko) | 2007-03-08 |
AU2005221712A1 (en) | 2005-09-22 |
CN1942202A (zh) | 2007-04-04 |
TNSN06273A1 (en) | 2007-12-03 |
US20060159672A1 (en) | 2006-07-20 |
ZA200607552B (en) | 2008-05-28 |
US7084247B2 (en) | 2006-08-01 |
JP2007528422A (ja) | 2007-10-11 |
WO2005087261A3 (en) | 2005-12-08 |
WO2005087261A2 (en) | 2005-09-22 |
MXPA06010364A (es) | 2007-03-07 |
US20050202034A1 (en) | 2005-09-15 |
MA28525B1 (fr) | 2007-04-03 |
EA200601671A1 (ru) | 2007-02-27 |
NO20064610L (no) | 2006-12-04 |
IL177961A0 (en) | 2006-12-31 |
CA2559065A1 (en) | 2005-09-22 |
EP1732595A2 (en) | 2006-12-20 |
AP2006003735A0 (en) | 2006-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508633A (pt) | identificação de antìgenos próprios e não próprios envolvidos em doenças auto-imunes | |
BR112013004056B8 (pt) | Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende | |
BR112012003064B8 (pt) | anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo | |
BRPI0607671A2 (pt) | anticorpo monoclonal dirigido contra o peptìdeo beta-amilóide, cadeia pesada, cadeia leve e fragmento de anticorpo, composição farmacêutica e uso da mesma, bem como polinucleotédeios, vetor e célula hospedeira compreendendo estes | |
TR201800669T4 (tr) | Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇ | |
BR112014017525A2 (pt) | composição farmacêutica que compreende um complexo de carga de carreador polimérico e pelo menos uma proteína ou antígeno de peptídeo | |
BR112012005713A2 (pt) | vacinas direcionadas a célula langerhans. | |
EA201291243A1 (ru) | Антитела против респираторно-синцитиального вируса (рсв) и способы их применения | |
BRPI0513798A (pt) | anticorpos anti-cd154 | |
BRPI0819909B8 (pt) | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica | |
ECSP10010251A (es) | ANTICUERPOS MONOCLONALES QUE SE UNEN AL hGM-CSF Y COMPOSICIONES MÉDICAS QUE LOS COMPRENDEN | |
BRPI0816784A8 (pt) | Fatores neuro-endócrinos para o tratamento de doenças degenerativas | |
AR067199A1 (es) | Proteinas de union a antigenos que se unen a par-2 | |
BR112014018561A8 (pt) | Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo | |
Strijbos et al. | A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis | |
ECSP088636A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer | |
BR112014029089A2 (pt) | anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2 | |
CO6602134A2 (es) | Proteinas de union a antigeno especificas para componente amiloide serico p | |
JOP20210265A1 (ar) | الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها | |
Barderas et al. | Isolation of the main allergen Fra e 1 from ash (Fraxinus excelsior) pollen: comparison of the natural and recombinant forms | |
Sule et al. | HIV-1 and-2 Antibodies among Children in Anyigba, Kogi State, Nigeria | |
WO2004018511A3 (en) | Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins | |
BR112016002001A2 (pt) | Medicamento compreendendo anticorpo antifosfolipase d4 | |
BR112022026533A2 (pt) | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo | |
BR112022002236A2 (pt) | Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011. |